C4 Therapeutics (CCCC)
(Delayed Data from NSDQ)
$6.32 USD
-0.11 (-1.71%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $6.33 +0.01 (0.16%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth F Momentum D VGM
Balance Sheet
Fiscal Year End for C4 Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 254 | 276 | 309 | 372 | 91 |
Receivables | 12 | 1 | 6 | 4 | 5 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 10 | 11 | 5 | 2 |
Total Current Assets | 271 | 288 | 326 | 381 | 97 |
Net Property & Equipment | 7 | 7 | 3 | 3 | 4 |
Investments & Advances | 28 | 61 | 142 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 6 | 5 | 4 | 3 | 3 |
Total Assets | 376 | 431 | 507 | 400 | 118 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 1 | 5 | 6 | 5 |
Current Portion Long-Term Debt | 0 | 2 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 21 | 20 | 14 | 10 | 7 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 15 | 17 | 32 | 28 | 21 |
Total Current Liabilities | 43 | 45 | 51 | 44 | 34 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 22 | 17 | 24 | 54 | 73 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 9 | 11 | 10 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 130 | 142 | 117 | 119 | 119 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 111 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 775 | 689 | 658 | 465 | 6 |
Retained Earnings | -528 | -396 | -268 | -184 | -117 |
Other Equity | 0 | -4 | -1 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 246 | 289 | 390 | 281 | -1 |
Total Liabilities & Shareholder's Equity | 376 | 431 | 507 | 400 | 118 |
Total Common Equity | 246 | 289 | 390 | 281 | -112 |
Shares Outstanding | 60.40 | 48.90 | 48.60 | 43.00 | NA |
Book Value Per Share | 4.07 | 5.91 | 8.02 | 6.53 | 0.00 |
Fiscal Year End for C4 Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 264 | 258 | 254 | 217 | 267 |
Receivables | 1 | 14 | 12 | 1 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 11 | 8 | 6 | 7 | 6 |
Total Current Assets | 276 | 280 | 271 | 224 | 274 |
Net Property & Equipment | 7 | 7 | 7 | 7 | 8 |
Investments & Advances | 32 | 41 | 28 | 30 | 19 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 6 | 9 | 6 | 7 | 7 |
Total Assets | 381 | 398 | 376 | 333 | 375 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 2 | 1 | 1 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 10 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 11 | 13 | 21 | 15 | 17 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 37 | 35 | 15 | 8 | 14 |
Total Current Liabilities | 54 | 55 | 43 | 30 | 48 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 17 | 21 | 22 | 20 | 25 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 134 | 140 | 130 | 117 | 141 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 822 | 815 | 775 | 711 | 702 |
Retained Earnings | -574 | -557 | -528 | -494 | -467 |
Other Equity | 0 | 0 | 0 | -1 | -2 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 247 | 258 | 246 | 216 | 234 |
Total Liabilities & Shareholder's Equity | 381 | 398 | 376 | 333 | 375 |
Total Common Equity | 247 | 258 | 246 | 216 | 234 |
Shares Outstanding | 69.30 | 68.80 | 60.40 | 49.20 | 49.00 |
Book Value Per Share | 3.57 | 3.75 | 4.07 | 4.39 | 4.77 |